TrialNature medicine2023

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Marion Thibaudin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.